Janux Therapeutics (JANX) Profit After Tax (2020 - 2026)

Janux Therapeutics (JANX) has reported Profit After Tax for 7 consecutive years, with -$24.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 3.63% year-over-year to -$24.4 million; the TTM figure through Mar 2026 stood at -$116.9 million (down 48.27% YoY), while the FY2025 annual figure was -$113.6 million, down 64.69% from the prior year.
• Profit After Tax rose to -$24.4 million in Q1 2026 per JANX's latest filing, from -$34.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$7.1 million in Q2 2024 and bottomed at -$34.3 million in Q4 2025.
• Historically, Profit After Tax has averaged -$19.6 million across 5 years, with a median of -$17.5 million in 2023.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 487.13% — and 2024, when it surged 60.45%.
• Janux Therapeutics' Profit After Tax stood at -$15.3 million in 2022, then gained by 20.92% to -$12.1 million in 2023, then slumped by 66.83% to -$20.2 million in 2024, then slumped by 69.89% to -$34.3 million in 2025, then grew by 29.07% to -$24.4 million in 2026.
• Business Quant data shows JANX's Profit After Tax at -$24.4 million in Q1 2026, -$34.3 million in Q4 2025, and -$24.3 million in Q3 2025.